The 2-pyridone antibacterial agents: Bacterial topoisomerase inhibitors

Medicinal Research Reviews

Volumn 20, Issue 4, 2000, Pages 231-293

  Qun, Li ^a   Mitscher, Lester A ^b   Shen, Linus L ^a  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Antiinfective agents; Bacterial resistance; Benzoxazines; Bioisosteres; DNA gyrase inhibitors; Fluoroquinolones; In vitro activity; In vivo activity; Naphthyridinones; Pyridopyri midines; Quinolizines

Indexed keywords

2 PYRIDONE DERIVATIVE; ANTIBIOTIC AGENT; DNA TOPOISOMERASE INHIBITOR;

ANTIMICROBIAL ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0342646918     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1128(200007)20:4<231::AID-MED1>3.0.CO;2-N     Document Type: Review

References (133)

1. Kojima T, Mitsuhashi S. History of quinolone antibacterials. Prog Drug Res 1992;38:11-17.
2. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP. 1,8-Naphthyridine derivatives. A new class of chemotherapeutic agents. J Med Chem 1962;5:1063-1065.
3. Albrecht R. Development of antibacterial agents of the nalidixic acid type. Prog Drug Res 1977;21: 9-104.
4. Koga H, Itoh A, Murayama S, Suzue S. Irikura T. Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. J Med Chem 1980;23: 1358-1363.
5. Boswell FJ, Wise R. Advances in the macrolides and quinolones. Lower Resp Tract Infect 1998;12: 647-670.
6. Ball P, Fernald A. Tillotson G. Therapeutic advances of new fluoroquinolones. Exp Opin Invest Drug 1998;7:761-783.
7. Kidwai M, Misra P, Kumar R. The fluorinated quinolones. Curr Pharm Des 1998:4:101-118.
8. (a) Quinolone antibacterials. Kuhlmann J, Dalhoff A, Zeiler HJ, editors. Handbook of experimental pharmacology, 127. Berlin: Springer-Verlag; 1998.
9. (b) The Quinolones. Andriole VT, editor. 2nd Ed. San Diego: Academic; 1998.
10. Gootz TD, Brighty KE. Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Med Res Rev 1996;16:433-486.
11. Hayashi K, Todo Y, Hamamoto S, Ojima K, Yamada M, Kito T, Takahata M, Watanabe Y, Narita H. T-3811, a new de-F(6)-quinolone: synthesis and in vitro activity of 7-(isoindolin-5-yl) derivatives. Abstract F158. 37th ICAAC; 1997.
12. Neu HC, Oercival A, Lode HE, editors. Ciprofloxacin: a major advance in quinolone chemistry. Am J Med 1987;82(4A):1-404.
13. Brickner SJ. Multidrug-resistant bacterial infections: driving the research for new antibiotics. Chem Ind 1997;131-135.
14. Stinson SC. Drug firms restock antibacterial arsenal. Chem Eng News 1996;74:75-100.
15. Suh B, Lorber B. Quinolones. Antimicrob Therapy II 1995;79:869-894.
16. Hendershot EF. Fluoroquinolones. Infect Dis Clin Nor Am 1995;9:715-730.
17. Doern GV. Mechanisms and current rates of resistance. Am J Manag Care 1998;4:S531-S537.
18. Roberts MC. Antibiotic-resistance in oral/respiratory bacteria. Crit Rev Oral Bio Med 1998;9: 522-590.
19. Jones RN, Pfaller MA. Bacterial resistance-a worldwide problem. Diagnos Microbio Infect Dis 1998; 31:379-388.
20. Bax RP, Anderson R, Crew J, Fletcher P, Johnson T, Kaplan E, Knaus B, Kristinsson K, Malek M, Strandberg L. Antibiotic-resistance - what can we do. Nat Med 1998;4:545-546.
21. Hare D. Microbial resistance to antimicrobial drugs. Can Vet J 1998;39:329-331.
22. Offner S. Antibiotic-resistant bacteria - there is hope. Am Bio Teacher 1998;60:430-433.
23. Baquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997;39:1-6.
24. Yee YC, Thornsberry CA. A survey of ciprofloxacin and 11 other antimicrobial agent susceptibility data of United States bacterial isolates from 1990 to 1992. Antimicrob Infect Dis Newslett 1995:14:1-18.
25. Hiramatsu K. Vancomycin resistance in staphylococci. Drug Resist Update 1998:1:135-150.
26. Mainardi JL. Staphylococci resistance to glycopeptides. Med Et Malad Infect 1997;27:940-942.
27. Grubb WB. Genetics of MRSA. Rev Med Microbio 1998:9:153-162.
28. Cunha BA. Penicillin-resistant pneumococci. Drugs Today 1998;34:31-35.
29. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory-tract isolates of Streptococcus-Pneumoniae in North-America - 1997 results from the Sentry Antimicrobial Surveillance Program. Clin Infect Dis 1998;27:764-770.
30. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998;27:S75-S83.
31. Cole ST, Telenti A. Drug resistance in Mycobacterium tuberculosis. Euro Respir J 1995;8:701s-713s.
32. Munro S, Mickelsen PA, Anderson M, Wilson ML, Robinson A, Walsh P, Meier FA, Campos JM, Hacek DM. Peterson LR, Reynolds JK, Allen SD, Pfaller MA, Jones RN, Valenstein P, Cockerill F, Gilligan PH, Wait K, Harrell LJ, Reller LB. Washington JA, Mann LM, Woods GL, Carroll KC, Reimer L. United States geographic bacteria susceptibility patterns. Am J Clin Pathol 1998;109:144-152.
33. Dominguez MA, Pallares R. Antibiotic-resistance in respiratory pathogens. Curr Opin Infect Dis 1998;11:139-145.
34. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus-pneumoniae, Haemophilus-influenzae, and Moraxella-catarrhalis in the United States in 1996-1997 respiratory season. Diagnos Microbio Infect Dis 1997;29:249-257.
35. Chopra I. Research- and-development of antibacterial agents. Curr Opin Microbio 1998;1:495-501.
36. Chu DTW, Plattner JJ, Katz L. New directions in antibacterial research. J Med Chem 1996;39: 3853-3874.
37. Piddock LJV. Antibacterials - Mechanisms of action. Curr Opin Microbio 1998;1:502-508.
38. Burghardt H, Schimz KL, Muller M. On the target of a novel class of antibiotics, oxazolidinones, active against multidrug-resistant Gram-positive bacteria. FEBS Lett 1998;425:40-44.
39. Zurenko GW, Ford CW, Hutchinson DK, Brickner SJ, Barbachyn MR. Oxazolidinone antibacterial agents; development of the clinical candidates eperzolid and linezolid. Exp Opin Invest Drugs 1997;6: 151-158.
40. Ford CW, Hamel JC, Stapert D, Moerman JK, Hutchinson DK, Barbachyn MR, Zurenko GE. Oxazolidinones: new antibacterial agents. Trends Microbio 1997;5:196-200.
41. Discotto LF, Pucci MJ, Lawrence LE, Barren JF. 38th Intersci conf on antimicrob agents chemother. Exp Opin Invest Drugs 1998;7:2061-2077.
42. Setti EL, Micetich RG. New trends in antimicrobial development. Curr Med Chem 1998;5:101-113.
43. Niccolai D, Tarsi L, Thomas R. The renewed challenge of antibacterial chemotherapy. J Chem Soc Chem Comm 1997;2333-2342.
44. Malabarba A, Nicas TI, Thompson RC. Structure modifications of glycopeptide antibiotics. Med Res Rev 1997;17:69-137.
45. Bryskier A. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 1998;27:865-883.
46. Domagala JM, Sanchez JP. New approaches and agents to overcome bacterial-resistance. Ann Rep Med Chem 1997;32:111-120.
47. Hogberg T, Vora M, Drake SD, Mitscher LA, Chu DTW. Structure-activity relationships among DNA-gyrase inhibitors. Synthesis and antibacterial evaluation of chromones and coumarins related to oxolinic acid. Acta Chem Scand B 1984;38:359-366.
48. Hogberg T, Khanna I, Drake SD, Mitscher LA, Shen LL. Structure-activity relationships among DNA gyrase inhibitors. Synthesis and biological evaluation of 1,2-dihydro-4,4-dimethyl-1-oxo-2-naphthale-necarboxylic acids as 1-carba bioisosteres of oxolinic acid. J Med Chem 1984;27:306-310.
49. Cecchetti V, Fravolini A, Fringuelli R, Schiaffella F. 4H-1-Benzothiopyran-4-one-3-carboxylic acids and 3,4-dihydro-2H-isothiazolo[5,4-b]benzothiopyran-3,4-diones as quinolone antibacterial analogs. J Heterocycl Chem 1993;30:1143-1148.
50. Li Q, Chu DTW, Claiborne A, Cooper CA, Lee CM, Raye K, Berst KB, Donner P, Wang W, Hasvold L, Fung A, Ma Z, Tufano M, Flamm R, Shen LL, Baranowski J, Nilius A, Alder J, Meulbroek J, Marsh K, Crowell D, Hui Y, Seif L, Melcher LM, Henry R, Spanton S, Faghih R, Klein LL, Tanaka SK, Plattner JJ. Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. J Med Chem 1996;39:3070-3088.
51. Chu DT, Li Q, Claiborne A, Raye KA, Cooper CS, Fung A, Lee CM, Tanaka SK, Shen LL, Donner P, Armiger YL, Plattner JJ. Synthesis and antibacterial activity of A-86719.1 and related 2-pyridones: a novel series of potent DNA gyrase inhibitors. Abstract F41. 34th ICAAC; 199.
52. Li Q, Chu DT, Lee CM, Raye KA, Shen LL, Tanaka SK, Alder J, Plattner JJ. Synthesis and activity of the bioisosteres of naphthyridine antibacterial agents. Abstract F764. 32nd ICAAC; 1992.
53. Chu DT, Li Q, Lee CM, Raye KA, Tanaka SK, Alder J, Plattner JJ. Recent advances in the chemistry of anti-infective agents. Bentley PH, Ponsford R, editors. Cambridge, England: Royal Soc Chem; 1993. p 94-105.
54. Alder DA. Determining the therapeutic potential of experimental antibacterial agents: the use of animal models. Curr Pharm Des 1997;3:143-158.
55. Fernandes PB, Chu DTW, Swanson RN, Ramer NR, Hanson CW, Bower RR, Stamm JM, Hardy DJ. A-61827 (A-60969), a new fluoronaphthyridine with activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1988;32:27-32.
56. Chu DTW, Fernandes PB, Claiborne AK, Gracey EH, Pernet AG. Synthesis and structure-activity relationships of new arylfluoronaphthyridine antibacterial agents. J Med Chem 1986;29:2363-2369.
57. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother 1997;39(B):1-14.
58. Chu DTW, Li Q, Tanaka K, Alder J, Claiborne A, Lico I, Raye K, Rosen T, Plattner JJ. Synthesis and biological properties of A-80556: a potent antibacterial fluoroquinolone. Abstract 652. 32nd ICAAC; 1992.
59. Rosen T, Chu DTW, Lico IM, Fernandes PB, Marsh K, Shen L, Cepa VG, Pernet AG. Design, synthesis, and properties of (4S)-7-(4-amino-2-substituted-pyrrolidin-1-yl)quinolone-3-carboxylic acids. J Med Chem 1988;31:1598-1611.
60. Clement JJ, Tanaka SK, Alder J, Vojtko C, Beyer J, Hensey D. Ramer N, McDaniel D, Chu DTW. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother 1994;38:1071-1078.
61. Marsh K, Eiden E, Hernandez L, Chu DTW. Pharmacokinetic profile of A-80556 in dog and rat. Abstract 654. 32nd ICAAC; 1992.
62. Li Q, Chu DTW, Raye K, Claiborne A, Seif L, Macri B, Plattner JJ. A practical stereoselective synthesis of (2S, 4S)-4-tert-butoxycarbonylamino-2-methylpyrrolidine. Tetrahed Lett 1995;36: 8391-8394.
63. Heck J, Thorsett UD. 4-Oxo-4H-quinolizine-3-carboxylic acids and derivatives thereof. US Patent 4,921,857; 1990.
64. Li Q, Sowin T, Claiborne A, Lijewski L, Zhang X, Raye K, Mazdiyasni H, Arnold W, Melcher LM, Wang W, Hasvold L, Fung T, Chu DTW, Plattner JJ. Practical synthesis of 2-pyridone core: ethyl 8-chloro-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizinone-3-carboxylate. Heterocyc 1999;51: 1345-1353.
65. Klein LL, DeGoey DA, Thomas SA, Yeung CM, Leone CL, Grampovnik DJ, Chu DT, Lartey PA. Preparation and antibacterial activity of pyridopyridone analogs: C-1 modifications. Bioorg Med Chem Lett 1997;7:1167-1170.
66. Chu DTW, DeGoey DA, Grampovnik DJ, Klein LL, Lartey PA, Leone CL, Thomas SA, Yeung CM. Process for preparing 1-substituted 8-chloro-7-fluoro-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid ethyl ester compounds. US Patent 5,789,591; 1998.
67. Wang W, Kerdesky FAJ, Hsiao CW, Li Q, Chu DT. Process for preparation of 4H-4-oxo-quinolizine-3-carboxylic acid. US Patent 5,693,813; 1997.
68. Klein LL, Yeung CM. Unpublished result.
69. Shen LL, Tanaka SK, Chu DTW. Quinolones, 2-pyridones and resistant type II DNA topoisomerases. Curr Pharm Des 1997;3:169-176.
70. Shen LL, Chu DTW. Type II DNA topoisomerases as antibacterial targets. Curr Pharm Des 1996;2: 195-208.
71. Li Q, Wang W, Berst KB, Claiborne A, Hasvold L, Raye K, Tufano M, Nilius A, Shen LL, Flamm R, Alder J, Marsh K, Crowell D, Chu DTW, Plattner JJ. Synthesis and structure-activity relationships of 2-pyridones. Part 2: 8-(fluoro-substituted pyrrolidinyl)-2-pyridones as antibacterial agents. Bioorg Med Chem Lett 1998;8:1953-1958.
72. Li Q, Claiborne A, Chu DTW, Lee CM, Raye KA, Berst K, Ma Z, Wang W, Shen LL, Flamm R, Nilius A, Alder J, Marsh K, Shortridge VD, Tanaka SK, Seif L, Cooper CS, Fung A, Tufano M, Melcher LM, Henry R, Klein L, Plattner JJ. Synthesis and in vitro antibacterial activity of novel DNA gyrase inhibitors. Abstract F8. 35th ICAAC; 1995.
73. Ma Z, Chu DTW, Li Q, Shen LL, Fung A, Cooper CS, Wang W, Wang S, Flamm RK, Nilius A, Alder JD, Tanaka SK, Or Y, Plattner JJ. Antibacterial 2-pyridones: consequence of structural modification at the C-8 position. Abstract F169. 37th ICAAC; 1997.
74. Armiger YL, Chu DTW, Fung AKL, Li Q, Wang W, Nilius A, Alder J, Ewing P, Stone G, Meulbroek J, Bui M, Shen LL, Paige L, Or YS, Plattner JJ. The discovery of A-165753 and A-170568, two potent broad spectrum antimicrobial agents. Abstract F86. 38th ICAAC; 1998.
75. Fung A, Chu DT, Armiger YL, Li Q, Tanaka SK, Flamm RK, Shen L, Baranowski J, Marsh K, Crowwell D, Plattner JJ. Synthesis and structure-activity relationships of 8-(3-(1-aminoalkyl)pyrrolidinyl)- and 8-(3-(1-aminocycloalkyl)-pyrrolidinyl)-2-pyridopyridone antibacterials. Abstract F9. 35th ICAAC; 1995.
76. Chu DT, Li Q, Cooper CS, Fung A, Lee CM, Plattner JJ, Ma Z, Wang W. Quinolizinone type compounds. WO Patent 9639407 1996;9:639-407.
77. Chu DT, Li Q, Cooper CS, Fung A, Lee CM, Plattner JJ. Quinolizinone type compounds. US Patent 5,580,872; 1996.
78. Chu DT, Li Q, Cooper CS, Fung A, Lee CM, Plattner JJ, Ma Z, Wang W. Quinolizinone type compounds. US Patent 5,726,182; 1998.
79. Chu DT, Li Q, Cooper CS, Fung A, Lee CM, Plattner JJ, Ma Z, Wang W. Quinolizinone type compounds. US Patent 5,599,816; 1997.
80. Goa KI, Bryson HM, Markham A. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability. Drugs 1997;53:700-725.
81. North DS, Fish DN, Redington JJ. Levofloxacin, a 2nd-generation fluoroquinolone. Pharmacother 1998;18:915-935.
82. Li Q, Claiborne A, Berst K, Raye K, Lee CM, Nilius A, Alder J, Marsh K, Shen LL. Unpublished result.
83. Chu DTW. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drug Exp Clin Res 1990;16:435-443.
84. Wang W, Hasvold L, Nilius A, Alder J, Marsh K, Shen LL. Unpublished result.
85. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials. J Antimicrob Chemother 1994;33:685-706.
86. Iwasaki H, Miyazaki S, Tsuji A, Yamaguchi K, Goto S. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Microbio 1995;41:100-112.
87. Dalhoff A, Petersen U, Endermann R. The in vitro activity of Bay-12-8039, a new 8-methoxyquinolone. Chemother 1996;42:410-425.
88. Petersen U, Bartel S, Bremm K, Himmier T, Krebs A, Schenke T. The synthesis and biological properties of 6-fluoroquinolone-carboxylic acids. Bull Soc Chim Belg 1996;105:683-699.
89. Park TH, Nam KS, Ha YH, Choi YK, Choi YJ, Kong JY, Kim YH. Synthesis and antibacterial activity of KRQ-10018 and its analogues: potent DNA gyrase inhibitors. Abstract F173. 37th ICAAC; 1997.
90. Pazufloxacin. Drugs Future 1996;21:846-854.
91. Wagstaff A, Balfour JA. Grepafloxacin. Drugs 1997;53:817-824.
92. Norrby SRE. New perspective on ofloxacin. Scand J Infect Dis Suppl 1990;68:1-69.
93. Chu DTW, Maleczka RE. Synthesis of 4-oxo-4H-quino[2.3.4ij]-benzoxazine-5-carboxylic acid derivatives. J Heterocycl Chem 1987;24:453-456.
94. Rad'l S, Zikn'n V. Synthesis and antibacterial activity of some 3-oxo-3H-pyrido[3,2,1-kl]phenoxazine-2-carboxylic acids. Collect Czech Chem Comm 1989;54:506-515.
95. Chu DTW, Li Q, Raye K. Benzo[5.6]pyrano[2,3,4-ij]quinolizine and benzo[5.6]thiopyrano[2,3,4-ij]quinolizine derivatives as antibacterial and antineoplastic agents. US Patent 5,618,813; 1997.
96. Miyamoto H, Ueda H, Otsuka T, Aki S, Tamaoka H, Tominaga M, Nakagawa K. Studies on antibacterial agents. III. Synthesis and antibacterial activities of substituted 1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acids. Chem Pharm Bull 1990;38:2472-2475.
97. Sanchez JP, Domagala JM, Hagen SE, Heifetz CL, Hutt MP, Nichols JB, Trehan AK. Quinolone antibacterial agents. Synthesis and structure-activity relationships of 8-substituted quinolone-3-carboxylic acids and 1,8-naphthyridine-3-carboxylic acids. J Med Chem 1988;31:983-991.
98. Sanchez JP, Gogliotti RD, Domagala JM, Gracheck SJ, Huband MD, Sesnie JA, Cohen MA, Shapiro MA. The synthesis, structure-activity, and structure-side-effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents. J Med Chem 1995;38:4478-4487.
99. Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase - IV - biochemical activities, physiological roles during chromosome-replication, and drug sensitivities. Biochim Biophys Acta 1998;1400: 29-43.
100. Khodursky AB, Cozzarelli NR. The mechanism of inhibition of topoisomerase-IV by quinolone antibacterials. J Bio Chem 1998;273:27668-27677.
101. Pan XS, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997;41:471-474.
102. Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbio 1994;13:641-653.
103. Frank KE, Devasthale PV, Gentry EJ, Ravikumar VT, Keschavarz-Shokri A, Mitscher LA, Nilius A, Shen LL, Shawar WR, Baker WR. A simple, inexpensive apparatus for performing of preparative scale solution phase multiple parallel synthesis of drug analogs. II. Biological evaluation of a retrospective library of quinolone antiinfective agents. Combin Chem High Throughput Screen 1998:1:89-99.
104. Khodursky AB, Zechiedrich EL, Cozzarelli NR. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA 1995;92:11801-11805.
105. Adams DE, Shekhtman EM, Zechiedrich EL, Schmid MB, Cozzarelli NR. The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication. Cell 1992;71:277-288.
106. Breines DM, Ouabdesselam S, Ng EY, Tankovic J, Shah S, Soussy CJ, Hooper DC. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother 1997;41:175-179.
107. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:1554-1558.
108. Blanche F, Cameron B, Bernard FX, Maton L. Manse B, Ferrero L, Ratet N, Lecoq C, Goniot A, Bisch D, Crouzet J. Differential behaviors of Staphylococcus aureus and Escherichia coli Type-II DNA topoisomerases. Antimicrob Agents Chemother 1996;40:2714-2720.
109. Shen LL. Unpublished data.
110. Alder J, Clement J, Meulbroek J, Shipkowitz N. Mitten M, Jams K, Oleksijew A, Hutch T Sr, Paige L, Flamm R, Chu D, Tanaka K. Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections. Antimicrob Agents Chemother 1995; 39:971-975.
111. Fromtling RA. ABT-719. Drugs Future 1995;20:1103-1108.
112. Flamm RK, Vojtko C, Chu DT, Li Q, Beyer J, Hensey D, Ramer N, Clement JJ, Tanaka SK. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 1995;39:964-970.
113. Flamm RK, Vojtko C, Ramer N, Beyer J, Li Q, Chu D, Clement JJ, Tanaka SK. Comparative in vitro activity of A-86719.1, a novel bacterial DNA gyrase inhibitor. Abstract F45. 34th ICAAC; 1994.
114. Nilius AM, Hensey-Rudloff DM, Almer LS, Fung A, Arminger YL, Chu D, Flamm RK. Comparative in vitro antibacterial activity of A-170568.1, a novel 2-pyridone antibacterial agent. Abstract F79. 38th ICAAC; 1998.
115. Eliopoulos GM, Wennersten CB, Cole G, Chu D, Pizzuti D, Moellering JRC. In vitro activity of A-86719.1, a novel pyridone antimicrobial. Abstract F43. 34th ICAAC; 1994.
116. Eliopoulos GMW, Cole G, Chu D, Pizzuti D, Moellering RC Jr. In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. Antimicrob Agents Chemother 1995;39:850-853.
117. Chin NX, Chu D, Neu HC. In vitro antibacterial activity of A-86719.1, a new class of DNA gyrase inhibitor. Abstract F49. 34th ICAAC; 1994.
118. Akasaka T, Kurosaka S, Uchida Y, Tanaka M, Sato K, Hayakawa I. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type-II topoisomerases. Antimicrob Agents Chemother 1998;42:1284-1287.
119. Flamm RK, Vojtko C, Ramer N, Li Q, Chu D, Clement JJ, Tanaka SK. Characterization of in vitro activity of A-86719.1, a novel bacterial DNA gyrase inhibitor. Abstract F47. 34th ICAAC; 1994.
120. Chin NX, Chu D, Huang HB, Neu HC. A-86719.1, a new class of DNA gyrase inhibitor, its time-killing activity, postantibiotic effect and assay condition effect. Abstract F51. 34th ICAAC; 1994.
121. Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, Tovcimak A, Nukkula M, Chu D, Alder JD. In-vivo efficacy of ABT-255 against drug-sensitive and drug-resistant Mycobacterium-tuberculosis strains. Antimicrob Agents Chemother 1998;42:2674-2677.
122. Alder JD, Meulbroek JA, Shipkowitz NL, Jarvis K, Mitten M, Oleksijew A, Hutch T, Paige L, Clement J, Tanaka SK. Efficacy of A-86719.1, a novel 2-pyridone gyrase inhibitor, for treatment of systemic lung and abscess infections in mice and rats. Abstract F53. 34th ICAAC; 1994.
123. Meulbroek JA. Oleksijew A, Tanaka SK, Alder JD. Efficacy of A-86719.1, a novel 2-pyridone gyrase inhibitor, for treatment of endocarditis, pyelonephritis and systemic infections caused by enterococci in mice. Abstract F55. 34th ICAAC; 1994.
124. Meulbroek JA, Oleksijew A, Tanaka SK, Alder JD. Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyclonephritis. J Antimicrob Chemother 1996;38:641-653.
125. Meulbroek J, Jarvis K, Mitten M, Oleksijew A, Alder J, Stone G, Nilius A, Flamm R, Armiger YL, Fung A, Or YS, Chu D, Plattner J. Efficacy of A-170568.1, a 2-pyridone antimicrobial compound, against experimental infections in rats caused by difficult-to-treat Gram-positive bacteria. Abstract F81. 38th ICAAC; 1998.
126. Gillespie SH, Kennedy N. Fluoroquinolones - a new treatment for tuberculosis. Int J Tuberculosis Lung Dis 1998;2:265-271.
127. Cabral JHM, Jackson AP, Smith CV, Shikotra N, Maxwell A, Liddington RC. Crystal structure of the breakage-reunion domain of DNA gyrase. Nature 1997;388:903-906.
128. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998;279:1504-1513.
129. Klabunde T, Sharma S, Telenti A, Jacobs WR, Sacchettini JC. Crystal-structure of GyrA intein from Mycobacterium-xenopi reveals structural basis of protein splicing. Nat Struct Bio 1998;5:31-36.
130. Lue N, Sharma A, Mondragon A, Wang JC. A 26 kDa yeast DNA topoisomerase I fragment: crystallographic structure and mechanistic implications. Structure 1995;3:1315-1322.
131. Maxwell A. Protein gates in DNA topoisomerase II. Nat Struct Bio 1996;3:109-112.
132. Stewart L, Redinbo MR, Qiu X, Hol WGJ, Champoux JJ. A model for the mechanism of action of human topoisomerase I. Science 1998;279:1534-1541.
133. Berger JM, Wang JC. Recent developments in DNA topoisomerase. II. Structure and mechanism. Curr Opin Struct Bio 1996;6:84-90.